PIK3CA mutations occur in 20–30% of patients with BC, with different prevalence among the various BC intrinsic subtypes, reported in approximately 45% of luminal A, 29% of luminal B, 39% of HER2-enriched and in 9% of basal-like BC [3]. Here, ERBB2 is linked to breast cancer.